The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 75%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (21 analysts) rates it buy, with a mean price target of $147.
Citigroup
C · a US exchange · USD · Market cap $229.4B · 224,000 employees
Citigroup Inc., a diversified financial service holding company, provides various financial products and services to consumers, corporations, governments, and institutions.
FAIL · Does not pass the screenAt the last full screen
2026-09-08
Screened 2026-09-08 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
This name holds its accumulation label.
Citigroup holds its Accumulation at $136.74. Consolidating, no directional conviction, held for 1 days.
| Phase | Accumulation |
| Quantitative state | Consolidating, no directional conviction, held for 1 days |
| Price at the screen | $136.74 |
| Valuation | 14.73 trailing · 10.61 forward price to earnings |
| Values screen | FAIL · score 10.0 |
| Beta | 1.10 |
Five Screens, Shown in Full
Does not pass. Business activity screen
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Excluded | Core business clean | Business activity: Financials sector | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Conscience OverlayThe quantitative screen above is arithmetic. Separately, community boycott lists cite this company: Cited by BDS movement for banking relationships and investment services connected to Israeli government entities and settlement-linked companies. The desk records that flag here without folding it into the verdict: the screen measures the balance sheet, the overlay informs the conscience, and they are different judgements that belong to different owners. The second one is yours.
The Fair Value Range
Our framework reads AVOID: it trades at roughly a 28% discount to our $175.37 fair value, narrow competitive moat, 15.50% revenue growth.
Fair value range in USD, drawn from the 2026-09-08 screen. The gold marker is the market price at the same screen. A 28.3% margin of safety to the base estimate.
Third-party analyst targets: 20 covering, consensus None. The average target sits +15% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-08 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsThe Financial Giant That Falls Short Ethically
When you think of banking services, a behemoth like Citigroup might come to mind, a company that offers a vast array of financial products to a diverse clientele. However, despite its size and scope, Citigroup fails to meet our ethical standards, and that's why we're steering clear.
Citigroup's financial performance isn't the issue; with a forward P/E of 10.1x, it's trading at a discount to its peers, and boasts a 16% revenue growth and a 22% profit margin. The question mark is its narrow moat and a 9% ROE, which suggests a less competitive edge and subpar returns on equity.
Yet, the real reason we avoid Citigroup lies in its ethical shortcomings. Despite the consensus buy rating from 20 analysts and a median target of $158, our ethical screen shows a fail, specifically on the business activity screen. This means that while the numbers might look appealing, the underlying activities of the company do not align with our strict ethical criteria.
Analysis, not advice.
| Forward P/E | 10.6xcheap for a company growing this fast |
| Trailing P/E | 14.7xreasonably valued |
| EPS, trailing | 9.28 |
| EPS, forward | 12.88 |
| Revenue growth | +15.5%steady growth |
| Profit margin | 21.8%healthy profit margins |
| Return on equity | 8.5%a modest return on shareholder capital |
| Dividend yield | 191.00% |
| Beta | 1.10moves a little more than the market |
| Short interest, float | 0.00% |
| 52-week range | 93.66 - 147.96 |
| Moat | NARROW |
| Market cap | $229.4B |
| Employees | 224,000 |
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeC trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 2.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 75%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (21 analysts) rates it buy, with a mean price target of $147.
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 16% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 75%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (21 analysts) rates it buy, with a mean price target of $147.
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- 3 Reasons to Avoid C and 1 Stock to Buy Instead StockStory · 22h ago
- Bank ETFs in Spotlight as Next Week's Fed Rate Hike Odds Hit 70% Zacks · 1d ago
- Can HSBC's Germany Pullback Support Profitability and Efficiency? Zacks · 1d ago
- Can Greece Add Another Growth Lever for JPMorgan in Europe? Zacks · 1d ago
- ECB's hawkish stance and rising energy prices prompt expectations of further rate hikes Reuters · 1d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-27 | Fraser Jane | CEO | Sale | 100,000 | $6,000,000 |
| 2026-05-26 | Mason Mark | CFO | Purchase | 10,000 | $595,000 |
| 2026-05-25 | Corbat Michael | Director | Award/Grant | 5,000 | · |
| 2026-05-24 | Forese James | Director | Option Exercise | 20,000 | $1,000,000 |
| 2026-05-23 | Gerspach John | CFO | Tax Withholding | 5,000 | $305,000 |
| 2026-05-22 | Crittenden Gary | Director | Gift | 2,000 | · |
| 2025-05-30 | Fraser Jane | CEO | Purchase | 50,000 | $2,900,000 |
| 2026-05-08 | DUGAN JOHN CUNNINGHAM | Director | 2,117 | $265,260 | |
| 2026-04-15 | SKYLER EDWARD | Officer | 25,000 | $3,285,350 | |
| 2026-04-15 | GILES NICOLE M. | Officer | 12,732 | $1,678,078 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 9 Sept2024 | Tracey Mann | Republican | sell | 1K–15K |
| 9 Sept2024 | Tracey Mann | Republican | sell | 1K–15K |
| 9 Sept2024 | Tracey Mann | Republican | sell | 1K–15K |
| 9 Sept2024 | Tracey Mann | Republican | sell | 1K–15K |
| 9 Sept2024 | Tracey Mann | Republican | sell | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $125.85 | +6.3% | · | $1,063 | +6.3% |
| 2 months | $123.80 | +8.0% | $0.60 | $1,085 | +8.5% |
| 3 months | $105.00 | +27.4% | $0.60 | $1,279 | +27.9% |
| 6 months | $110.64 | +20.9% | $1.20 | $1,220 | +22.0% |
| 1 year | $76.30 | +75.3% | $2.40 | $1,784 | +78.4% |
| 2 years | $58.10 | +130.2% | $4.64 | $2,382 | +138.2% |
| 3 years | $43.78 | +205.5% | $6.76 | $3,209 | +220.9% |
| 5 years | $64.33 | +107.9% | $10.84 | $2,248 | +124.8% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever C does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.